Our customers produce more product, at a lower cost, and more consistently by integrating our IP-protected bioprocessing reagents into their cell culture systems.
Our enzymatic solutions address cell-to-cell adhesion in large-scale culture systems, enabling a 75% + increase in cell viability and a 3-fold increase in productivity. Our products do not negatively interact with cell functionality or target proteins, are easy to integrate, and once integrated, generate annual revenues per supply contract of £4 - £10m.
Problem we are solving
Cells are powerful, whether in the body or in vitro. Globally, cells are being used to treat previously incurable diseases and develop vaccines to protect entire nations. However, for decades, cell manufacturing has suffered from inefficiencies directly related to the natural behaviour of cells to form tissues; they stick to each other.
When they stick together, a large proportion of cells cannot access oxygen and nutrients, so they die. This results in process loss of between 20 – 85% with sticky cell-related bottlenecks (clumping and aggregation) acknowledged across several modalities, including viral vaccines, gene therapies, and the nascent field of cell therapies. These inefficiencies can result in entire batches being lost (wasted resources), clinical programs failing due to cost and quality-related metrics, extended R&D cycles, and, worst of all, an inability to provide access to life-saving vaccines and treatments for hundreds of millions of people.
Our primary focus is on addressing inefficiencies in viral vaccine processes, where we can demonstrate significant yield increases. This specific market opportunity is valued at 250m USD.
Solution
What if we could maximise the production efficiency of every batch, increase yields, enable broader supply, and reduce costs to improve accessibility with the adoption of a simple bioprocessing reagent?
CellRev utilises enzymes to cleave the bridges between cells caused by their natural tendency to stick together. We do this using enzymes designed to act upon target extracellular matrix components, a naturally expressed substance in every cell. Our approach is gentle on the cells, so functionality is unaffected, and our enzymes do not interact with target proteins, nor impact infection/transfection processes.
Once integrated, our bioprocessing reagents act to prevent aggregation and clumping in cell culture systems, which increases cell culture homogeneity and cell viability, thus promoting process yields with 2-3-fold increases in viral titre evidenced. AggreGuard, our principal product, is a must-have in every new and existing microcarrier-based process.
Our solution is easy to adopt, yet the results are transformative. Imagine using the same capital equipment, yet producing 3x as many doses per annum.
Live Cells. Lives Saved.
